ArticleBMC ophthalmology2025
Comparison of the effects of spectacle lenses with highly aspherical lenslets combined with atropine for moderate to high myopia control in children.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Current Evidence on Options and Efficacy of Combination Therapy for Myopia Control-A Narrative Review.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Review
- Comparable myopia control efficacy of highly aspherical lenslets and diffusion optics technology spectacle lenses: a one-year real-world cohort study.BMC ophthalmology · 2026Article
- Control effect of dual-mechanism myopia control lenses on myopia in children and adolescents: a prospective, 12-month, non-randomized, parallel-controlled, and single-center trial protocol.Frontiers in medicine · 2026Article
- Comparison of myopia control efficacy between single vision and highly aspherical Lenslet spectacle lenses in children with low myopia: a 1-year retrospective study.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the 1-year myopia control effects of spectacle lenses with highly aspherical lenslets (HAL), HAL combined with 0.01% atropine (HALA), and single-vision spectacle lenses (SVL) in children with moderate to high myopia.
methodsThis retrospective cohort study analyzed 175 myopic children treated at the Eye Hospital of Wenzhou Medical University between January 2020 and January 2024. Participants were divided into three groups based on treatment: HAL (n = 62), HALA (n = 55), and SVL (n = 58). Changes in axial length (AL) and spherical equivalent refraction (SER) under non-cycloplegic conditions were compared using one-way ANOVA. Post hoc pairwise comparisons were performed using the LSD method, and all pairwise p-values were subsequently adjusted for multiple comparisons using the false discovery rate (FDR) to control the risk of Type I error.
resultsAfter 12 months, mean AL elongation was 0.21 ± 0.15 mm in the HAL group, 0.21 ± 0.13 mm in the HALA group, and 0.28 ± 0.15 mm in the SVL group. AL changes between HAL and HALA were not significantly different (P = 0.837). However, both HAL (P = 0.004) and HALA (P = 0.009) significantly slowed axial elongation compared to SVL. In subgroup analysis, children aged 8-10 years showed no significant differences among groups. In the 11-12-year subgroup, both HAL and HALA significantly reduced AL elongation compared to SVL, with no difference between HAL and HALA.
conclusionHAL and HALA offer similar efficacy in controlling myopia progression in children with moderate-to-high myopia, both outperforming SVL. Their effects appear more pronounced in older children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.